Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy
about
Biomarkers in Exhaled Breath Condensate Are Not Predictive for Pulmonary Exacerbations in Children with Cystic Fibrosis: Results of a One-Year Observational StudyVoice disorder in cystic fibrosis patients.Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.Polymicrobial challenges to Koch's postulates: ecological lessons from the bacterial vaginosis and cystic fibrosis microbiomes.Emergent properties of proteostasis in managing cystic fibrosis.Higher mobility scores in patients with cystic fibrosis are associated with better lung function.Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.Burkholderia cepacia complex: clinical course in cystic fibrosis patients.Future directions in early cystic fibrosis lung disease research: an NHLBI workshop reportAssociation Between Outcomes and Demographic Factors in an Azeri Turkish Population With Cystic Fibrosis: A Cross-Sectional Study in Iran From 2001 Through 2014.Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients.Yoga as a Therapy for Adolescents and Young Adults With Cystic Fibrosis: A Pilot Study.Extracellular matrix lumican promotes bacterial phagocytosis, and Lum-/- mice show increased Pseudomonas aeruginosa lung infection severity.Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis.Chest CT abnormalities and quality of life: relationship in adult cystic fibrosis.Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitisYoga Therapy in Children with Cystic Fibrosis Decreases Immediate Anxiety and Joint Pain.Methicillin-resistant Staphylococcus aureus in cystic fibrosis patients: do we need to care? A cohort study.What can the CF registry tell us about rare CFTR-mutations? A Belgian study.Decline in lung function does not predict future decline in lung function in cystic fibrosis patients.Expression of pro-inflammatory interleukin-8 is reduced by ayurvedic decoctions.Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis.Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.High usability of a smartphone application for reporting symptoms in adults with cystic fibrosis.A smartphone application for reporting symptoms in adults with cystic fibrosis: protocol of a randomised controlled trial.Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis.Improvements in symptomatic treatment strategies for cystic fibrosis: delivering CF care in the 21st century
P2860
Q28551208-751327C2-2533-4861-B130-63C7A2155755Q30438693-18720BD0-19F7-4210-B44D-577379CCC2E9Q33861117-81A5DED9-B7E9-44F9-9A41-F645E6066485Q33957168-5AE76AA1-1261-459C-BF83-FF3BA074B662Q34155594-801DEDF7-8114-4191-BE06-D36CEC6D214DQ34179233-2C4EF139-EC59-4E37-9CC4-B7EDFD4BFCF3Q34576386-61991774-3E36-442C-AF0C-D44F90A5E81CQ35144062-2AF59C12-38BD-4869-A86F-439335B06B2DQ35801062-9E889212-4137-4C13-B54D-DC01A66C9062Q35862661-11874810-5AAA-4BD4-AACC-F66FE8B3CF7BQ35988949-DBA3718E-B3AB-4D61-82E7-6649E7889D80Q36044728-8759E9CF-DAC8-449E-A8C0-9E741C6F67F6Q36171630-CC327932-70E2-4907-A2F7-BBEA195C0D00Q36301011-933AF3C7-9FF5-45C8-A97F-F90CC3DC39AAQ36332751-91755F8A-1998-4F97-A197-42040AACAB39Q36639773-EEAE25EB-C35A-4C4F-9297-42EC6D8F9438Q36685712-DA9DD7C7-DCAF-46B4-9A8B-C8A62530D2F1Q36754710-9B7AF7C3-9D49-426F-A58A-25D3F775C843Q37548041-C1CB21C3-852F-49C9-ADB3-20769E44D681Q38612479-33C3FFB0-799F-4266-A1BC-AAA11EDA9DB8Q38613628-3EE3953A-EEC6-4287-A771-794170375DB3Q38994413-888301CD-8930-45FF-808C-A5B1FEC2F22FQ39036966-82E5A2BF-89E2-44DE-9383-EB60CFD7FB35Q39685797-0251C74F-17B1-4CB8-953C-9A555D0D864EQ41148531-18AD4C44-CF68-4BCF-A777-55A20D66E4E6Q41907045-76364473-AC40-45E5-9440-32E28395826CQ43200814-823E19E4-689D-44E5-A6C9-F45D81E4F00DQ47669874-E7B5B8F7-5729-45A7-8C60-902A9951C3D9Q52572128-9624F49D-8154-449F-864F-DC7F23FD8D55Q53029501-D7713ABF-2E30-42B5-BA25-F4EE3E47D54CQ57913519-86016FEE-4D13-4DAD-BCF4-87C12C858823
P2860
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Measuring and improving respir ...... ties and challenges to therapy
@ast
Measuring and improving respir ...... ties and challenges to therapy
@en
type
label
Measuring and improving respir ...... ties and challenges to therapy
@ast
Measuring and improving respir ...... ties and challenges to therapy
@en
prefLabel
Measuring and improving respir ...... ties and challenges to therapy
@ast
Measuring and improving respir ...... ties and challenges to therapy
@en
P2093
P2860
P1476
Measuring and improving respir ...... ties and challenges to therapy
@en
P2093
Alexandra L Quittner
Bruce Marshall
Edith T Zemanick
Frank J Accurso
George Retsch-Bogart
J Kirk Harris
Lisa Saiman
Michael W Konstan
Steven Conway
P2860
P356
10.1016/J.JCF.2009.09.003
P577
2009-10-14T00:00:00Z